Physician profile
Madison E Beckley
NPI 1780341826
$6,851.84
in general payments reported to CMS, 2019-2025
29 companies · $1,869 in 2025
The $1,869 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.04 · 2022: $1,257 · 2023: $1,783 · 2024: $1,924 · 2025: $1,869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,524 · Education: $52.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,524.24 |
| Education | $52.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $944.06 | 2022-2025 | Jynarque, Voyxact |
| Alexion Pharmaceuticals, INC. | $814.09 | 2022-2025 | Ultomiris |
| Travere Therapeutics, INC. | $654.62 | 2024-2025 | Filspari |
| Calliditas Therapeutics US INC. | $641.55 | 2022-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals Lp | $619.88 | 2022-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $600.36 | 2022-2025 | |
| Amgen INC. | $559.85 | 2022-2025 | Tavneos, Krystexxa |
| Vifor Pharma, INC. | $556.36 | 2022-2025 | Veltassa, Korsuva |
| Mallinckrodt Hospital Products INC. | $284.88 | 2022-2024 | Acthar |
| Ardelyx, INC. | $189.09 | 2024-2025 | Ibsrela |
| Aurinia Pharma U.S., INC. | $142.97 | 2022-2024 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $129.45 | 2024-2025 | |
| Nxstage Medical, INC. | $107.68 | 2024 | |
| Akebia Therapeutics INC | $97.83 | 2022 | |
| Opko Pharmaceuticals, LLC | $57.09 | 2022-2023 | Rayaldee |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $52.83 | 2024 | Velphoro |
| Glaxosmithkline, LLC. | $52.74 | 2023-2025 | Arexvy, Benlysta |
| Abbvie INC. | $42.98 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $42.97 | 2023-2024 | Crysvita |
| Merck Sharp & Dohme LLC | $41.10 | 2025 | Prevymis |
| Takeda Pharmaceuticals U.S.A., INC. | $39.26 | 2024-2025 | Eohilia, Gattex |
| Genzyme Corporation | $32.07 | 2023 | |
| Scpharmaceuticals INC. | $26.31 | 2025 | |
| Apellis Pharmaceuticals, INC. | $23.67 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.00 | 2024 | Jardiance |
| Kyowa Kirin, INC. | $21.10 | 2023 | Crysvita |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.66 | 2023 | |
| Radiometer America, INC | $18.42 | 2025 | |
| Horizon Therapeutics Plc | $15.97 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison Beckley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.